Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Pharma/Fine Chemicals Roundup – September 20
7:38 AM MDT | September 20, 2011 | Deepti Ramesh
FDA ISSUES WARNING LETTER TO LONZA PLANT IN U.S. The U.S. Food and Drug Administration (FDA) issued a warning letter earlier this month to Lonza’s manufacturing plant at Hopkinton, MA, for deviating from current good manufacturing practice (cGMP). An FDA inspection from April 4, 2011 to May 6, 2011 at Lonza’s pharmaceutical and active pharmaceutical ingredient (API) manufacturing facility at Hopkinton identified significant violations of cGMP regulations for finished pharmaceuticals, and from cGMP for the manufacture of APIs, FDA says. Lonza responded...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee